Related references
Note: Only part of the references are listed.Hyperuricemia and its association with adiposity and dyslipidemia in Northwest China: results from cardiovascular risk survey in Xinjiang (CRS 2008-2012)
Fen Liu et al.
LIPIDS IN HEALTH AND DISEASE (2020)
Effects of the CB1 Receptor Antagonists AM6545 and AM4113 on Insulin Resistance in a High-Fructose High-Salt Rat Model of Metabolic Syndrome
Basma G. Eid et al.
MEDICINA-LITHUANIA (2020)
Preliminary screening of the possible protective effect of Moroccan propolis against chromium-induced nephrotoxicity in animal model
Soukaina El-Guendouz et al.
VETERINARY WORLD (2020)
A patent update on cannabinoid receptor 1 antagonists (2015-2018)
George Amato et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development
Thuy Nguyen et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
Endocannabinoid System and the Kidneys: From Renal Physiology to Injury and Disease
Janice T. Chua et al.
CANNABIS AND CANNABINOID RESEARCH (2019)
Pathophysiology of the metabolic syndrome
Emma McCracken et al.
CLINICS IN DERMATOLOGY (2018)
The Global Epidemic of the Metabolic Syndrome
Mohammad G. Saklayen
CURRENT HYPERTENSION REPORTS (2018)
The role of cannabinoid signaling in acute and chronic kidney diseases
Federica Barutta et al.
KIDNEY INTERNATIONAL (2018)
Peripheral CB1 Receptor Neutral Antagonist, AM6545, Ameliorates Hypometabolic Obesity and Improves Adipokine Secretion in Monosodium Glutamate Induced Obese Mice
Haiming Ma et al.
FRONTIERS IN PHARMACOLOGY (2018)
Cannabinoid Receptor Signaling in Central Regulation of Feeding Behavior: A Mini-Review
Marco Koch
FRONTIERS IN NEUROSCIENCE (2017)
Manifestations of Renal Impairment in Fructose-induced Metabolic Syndrome
Kameliya Bratoeva et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2017)
Metabolic syndrome: pathophysiology, management, and modulation by natural compounds
Yogita Rochlani et al.
THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE (2017)
The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability
Aliou B. Gueye et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2016)
Metabolic syndrome update
Scott M. Grundy
TRENDS IN CARDIOVASCULAR MEDICINE (2016)
Cannabinoid receptor 1 is a major mediator of renal fibrosis
Lola Lecru et al.
KIDNEY INTERNATIONAL (2015)
Association of fructose consumption and components of metabolic syndrome in human studies: A systematic review and meta-analysis
Roya Kelishadi et al.
NUTRITION (2014)
Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy
Tony Jourdan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Acute and chronic systemic CB1 cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive (mRen2) 27 rats
Chris L. Schaich et al.
PHYSIOLOGICAL REPORTS (2014)
Transforming growth factor-β/Smad signalling in diabetic nephropathy
Hui Yao Lan
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2012)
The neutral cannabinoid CB1 receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat
Nina L. Cluny et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2011)
Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome
James C. Russell et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2010)
A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents
N. L. Cluny et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy
Federica Barutta et al.
DIABETES (2010)
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity
Joseph Tam et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Mechanisms of Tubulointerstitial Fibrosis
Michael Zeisberg et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Inhibition of capillary repair in proliferative glomerulonephritis results in persistent glomerular inflammation with glomerular sclerosis
Yukinari Masuda et al.
LABORATORY INVESTIGATION (2010)
Dietary fructose causes tubulointerstitial injury in the normal rat kidney
Takahiro Nakayama et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2010)
Fructose induces the inflammatory molecule ICAM-1 in endothelial cells
Olena Glushakova et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Effect of genistein, a soy isof lavone, on whole body insulin sensitivity and renal damage induced by a high-fructose diet
Nallasamy Palanisamy et al.
RENAL FAILURE (2008)
The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats
Kelly S. Sink et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats
P. Janiak et al.
KIDNEY INTERNATIONAL (2007)
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats
Magali Gary-Bobo et al.
HEPATOLOGY (2007)
Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks
Kishore M. Gadde et al.
CIRCULATION (2006)
Renal manifestations in the metabolic syndrome
Francesco Locatelli et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat
NL Alderson et al.
DIABETOLOGIA (2004)
Anandamide decreases glomerular filtration rate through predominant vasodilation of efferent arterioles in rat kidneys
Y Koura et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
Share Paper
